{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:28:47Z","timestamp":1762223327976,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bioorg.2025.108590","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T19:20:52Z","timestamp":1747336852000},"page":"108590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel diarylurea derivatives as potent type II TRK inhibitors for combating multiple acquired resistant mutants"],"prefix":"10.1016","volume":"162","author":[{"given":"Wei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhendong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108590_bb0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: a bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108590_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-536-7_1","article-title":"The neurotrophin family of neurotrophic factors: an overview","volume":"846","author":"Skaper","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108590_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2025.108590_bb0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108590_bb0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108590_bb0030","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/acs.jmedchem.8b01092","article-title":"Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application","volume":"62","author":"Yan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108590_bb0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/13543776.2020.1737011","article-title":"Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019","volume":"30","author":"Bailey","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108590_bb0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.108590_bb0045","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1158\/1078-0432.CCR-21-0465","article-title":"Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion Cancer","volume":"27","author":"Laetsch","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108590_bb0050","doi-asserted-by":"crossref","first-page":"15503","DOI":"10.1021\/acs.jmedchem.1c01539","article-title":"Discovery of next-generation tropomyosin receptor kinase inhibitors for combating multiple resistance associated with protein mutation","volume":"64","author":"Zhuo","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108590_bb0055","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/acs.jmedchem.3c01645","article-title":"Discovery, Optimization, and evaluation of novel Pyridin-2(1H)-one analogues as potent TRK inhibitors for Cancer treatment","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108590_bb0060","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108590_bb0065","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: A New 3-Aminoindazole As a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108590_bb0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N","volume":"378","author":"Drilon","year":"2018","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108590_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108590_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cancergen.2021.12.002","article-title":"NTRK point mutations and their functional consequences","volume":"262-263","author":"Rogers","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bioorg.2025.108590_bb0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108590_bb0090","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108590_bb0095","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s42003-020-01508-w","article-title":"NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors","volume":"3","author":"Somwar","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bioorg.2025.108590_bb0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.apsb.2023.11.010","article-title":"Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib","volume":"14","author":"Xiang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.108590_bb0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/2159-8290.CD-20-0571","article-title":"TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors","volume":"11","author":"Cocco","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108590_bb0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/ml200261d","article-title":"Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent Cancer tumor models. ACS","volume":"3","author":"Albaugh","year":"2012","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108590_bb0115","first-page":"1731","article-title":"Insights into current tropomyosin receptor kinase (TRK) inhibitors","volume":"62","author":"Yan","year":"2019","journal-title":"Dev. Clin. Appl. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108590_bb0120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825004705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825004705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:26:27Z","timestamp":1762223187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825004705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"alternative-id":["S0045206825004705"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108590","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel diarylurea derivatives as potent type II TRK inhibitors for combating multiple acquired resistant mutants","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108590"}}